Company Overview and News
Estimates for NextEra Energy Partners (NEP - Free Report) have been revised upward over the past 60 days, reflecting analysts’ confidence in the stock. The Zacks Consensus Estimate for 2018 and 2019 earnings has moved 73.1% and 5.7% north to $2.96 and $2.22, respectively. Units of the partnership have rallied nearly 18.7% over the past six months compared with its industry’s rally of 10.3%. NextEra Energy Partners is a growth-oriented limited partnership formed by NextEra Energy, Inc.
The Fidelity MSCI Utilities Index ETF (FUTY - Free Report) was launched on 10/21/2013, and is a passively managed exchange traded fund designed to offer broad exposure to the Utilities - Broad segment of the equity market.
DUKH FENY FDIS VPU DUK FSTA FUTY NEE
NiSource, Inc.’s (NI - Free Report) business unit, Columbia Gas of Massachusetts, recently announced plans to replace the complete natural gas distribution system in the Merrimack Valley. The unit will collaborate with the Governor’s Office and stakeholders. Notably, the replacement involves 48-mile cast iron and bare steel pipeline system, which serves nearly 8,600 customers. The pipeline was severely affected by Hurricane Florence which hit Columbia on Sep 13, 2018.
NI DUKH YUM DUK FE NEE
Oil production is surging in North America but producers are far from happy as their profit margin is sinking. They are struggling to stay competitive owing to the infrastructural bottlenecks. As if the pipeline pinch problem was not enough for the United States and Canada, raging protests against the already approved and existing pipeline projects have made things worse.
DCUB SOJA DCUA DCUD DCUC CY UGI WGL ENB SJIU EQM KMI DRUA TRP EBBNF PAA ED KMR CVB NEE SO ENBBF DUKH TRP SJI D NJR DUK RGCO ENB ETP KMRFZ GJP
Targa Resources Corporation (TRGP - Free Report) recently inked a deal to offload its petroleum terminals and crude oil storage facilities in Baltimore and Tacoma. Houston-based Targa will divest these properties to ArcLight Capital Partners, LLC, which is headquartered in Boston, for $160 million. Subject to satisfactory closing conditions, the deal is set for culmination in the fourth quarter of 2018.
MPLX MPC KMI KMR TRGP CVB KMRFZ NEE
As a great admirer of Warren Buffett I read a great many books on his investment strategy. While being inspired by his long-term value approach to investing, however, I am also left with the feeling that this great investor has overlooked one crucial point. That is, “What is the impact of an investment on society and the environment in the long run?” Investing in a company lowers its cost of capital, therefore giving it more access to growth capital.
RDS.B RDS.A RDSB ESG RDSA RYDBF RYDAF INTC MCD NEE
NextEra Energy Partners (NEP - Free Report) announced that it has entered into an agreement with NextEra Energy’s (NEE - Free Report) unit, NextEra Energy Resources, to acquire renewable assets situated in eight states across the nation. The 11 wind and solar projects will collectively produce nearly 1,388 megawatts (MW) and expand the green power capacity of the company beyond 5,200 MW. This decision of acquisition is in line with the strategy of the partnership to replace the aging and uneconomic old fossil-fuel plants with new renewable generation plants.
NRGEO NRG AEE KHC NEP NEE
The theory regarding utility stocks to buy was simple: Robust economic growth coupled with a full labor market was supposed to spark rising inflation. The Fed was supposed to fight rising inflation with rate hikes. Fixed income yields were supposed to rise. Utility stocks, which were long viewed as bond substitutes in an era of ultra-low interest rates, were supposed to fall.
AWK AMZN SRE AEP NEE
Midstream had a rough week, the worst since late March and 4th worst so far this year. Oil prices rallied for a second straight week, NGL prices were sharply higher, the broad stock market was higher again, but midstream and MLPs lagged badly.
NGL CCR TGE ENB CEQP GNE EQM KMI TRP WMB AMGP OKE ED KMR CVB GEL NEE TRP VLP RGCO ENB ETP GNE TRGP PBA KMRFZ
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to NEE / NextEra Energy, Inc. on message board site Silicon Investor.
as of ET